A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer

Trial Profile

A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Cabazitaxel (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 According to trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, the trial is open at 2 sites and managed by the Prostate Cancer Clinical Trials Consortium (PCCTC).
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Jan 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top